merck

April 16 (Reuters) - Merck & Co said on Sunday it will buy Prometheus Biosciences Inc for about $10.8 billion, taking a promising experimental treatment for ulcerative colitis and Crohn's disease and building the presence its in…

The findings suggest that adding a personalized cancer vaccine based on mRNA technology to Keytruda, which improves the immune response, could prolong the time patients have without recurrence or death, said Dr. Jeffrey Weber of the NYU…